Título: Professor Associado
E-mail: [email protected]
Lattes: http://lattes.cnpq.br/4313449638231391
Orcid: ID 0000-0002-1128-7292 – https://orcid.org/0000-0002-1128-7292
Scopus: ID 56310968200 – https://www.scopus.com/authid/detail.uri?authorId=56310968200
Google scholar: ID 1jhdy0maaaaj – https://scholar.google.com.br/citations?user=1jhdY0MAAAAJ&hl=pt-BR&oi=ao
Research ID: P-8336-2015 – https://publons.com/researcher/2326878/olavo-pires-camargo/

Line of research:

Oncological Orthopedics – Resection and reconstruction of bone and soft tissue tumors.

Summary

We emphasize the diagnosis and treatment of bone and soft tissue tumors with reconstruction with modular endoprostheses and with allografts. We also focus on resections of soft tissue tumors of the extremities with microsurgical reconstruction and intraspinal locked nail fixation and modular endoprosthesis in metastatic bone lesions.

Relevant articles:

  1. Petrilli AS, Gentil FC, Epelman S, Lopes LF, Bianchi A, Lopes A, Figueiredo MT, Marques E, De Bellis N, Consentino E, et al. Increased survival, limb preservation, and prognostic factors for osteosarcoma. Cancer. 1991;68(4):733-7.
  2. Meirelles ES, Borelli A, Camargo OP. Influence of disease activity and chronicity on ankylosing spondylitis bone mass loss. Clin Rheumatol. 1999;18(5):364-8.
  3. Petrilli AS, de Camargo B, Filho VO, Bruniera P, Brunetto AL, Jesus-Garcia R, Camargo OP, Pena W, Péricles P, Davi A, Prospero JD, Alves MT, Oliveira CR, Macedo CR, Mendes WL, Almeida MT, Borsato ML, dos Santos TM, Ortega J, Consentino E; Brazilian Osteosarcoma Treatment Group Studies III and IV. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol. 2006;24(7):1161-8.
  4. Cabrita HB, Croci AT, Camargo OP, Lima AL. Prospective study of the treatment of infected hip arthroplasties with or without the use of an antibiotic-loaded cement spacer. Clinics (Sao Paulo). 2007;62(2):99-108.
  5. Bispo Júnior RZ, Camargo OP. Prognostic factors in the survival of patients diagnosed with primary non-metastatic osteosarcoma with a poor response to neoadjuvant chemotherapy. Clinics (Sao Paulo). 2009;64(12):1177-86.